ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury. By Crawford and Moul 2015

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. By D’Angelillo et al. 2014

The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada. By Davis et al. 2014

Bone health management in men undergoing ADT: examining enablers and barriers to care. By Damji et al. 2014 

Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. By Tsai et al. 2014

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. By Dueregger et al. 2014 

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. By Sammon et al. 2014 

Is there any harm in using ADT as a first line treatment for PCa?

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer. By Taguchi et al. 2014 

Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. By Taplin et al. 2014